Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Histone deacetylase (HDAC) inhibitors can modify tumor cell immunogenicity for immunotherapy.
• HDAC inhibitors reduce PD-L1 and increase MHCA expression, enhancing checkpoint inhibitor activity.
• Autophagosome formation is a cellular process involved in degradation and recycling.

Purpose of the Study:

• To investigate the role of drug combinations inducing autophagosome formation in modulating tumor cell immunogenicity.
• To explore the impact of these combinations on HDAC proteins and their regulation of PD-L1 and MHCA.
• To determine if enhanced autophagosome formation can facilitate immunotherapy with checkpoint inhibitors.

Main Methods:

• Utilized drug combinations known to induce rapid and intense autophagosome formation.
• Investigated the effect of these drugs on HDAC protein expression and signaling pathways.
• Analyzed changes in PD-L1 and MHCA expression on tumor cells.
• Examined the internalization of growth factor receptors and mutant RAS proteins into autophagosomes.
• Assessed the role of lysosomal degradation in reducing HDAC and signaling protein expression.

Main Results:

• Drug combinations promoting autophagosome formation modulate HDAC protein expression.
• These combinations lead to the internalization of growth factor receptors and mutant RAS proteins into autophagosomes.
• HDAC and signaling proteins within autophagosomes are reduced via lysosomal degradation.
• Tumor cell immunogenicity is altered, potentially enhancing responses to checkpoint inhibitors.

Conclusions:

• Strong induction of autophagosome formation and autophagic flux represents a promising strategy.
• This strategy may enhance the effectiveness of subsequent cancer immunotherapies using checkpoint inhibitor antibodies.
• Targeting autophagic pathways offers a novel approach to improve cancer treatment outcomes.